Immix Biopharma’s (IMMX) Buy Rating Reaffirmed at HC Wainwright

Immix Biopharma (NASDAQ:IMMX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 207.02% from the company’s previous close.

Immix Biopharma Stock Performance

Shares of NASDAQ IMMX opened at $2.28 on Monday. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $6.87. The stock’s 50-day simple moving average is $2.00 and its 200-day simple moving average is $1.95. The firm has a market cap of $62.72 million, a price-to-earnings ratio of -2.68 and a beta of 0.27.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). As a group, research analysts predict that Immix Biopharma will post -0.64 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immix Biopharma stock. Geode Capital Management LLC grew its stake in Immix Biopharma, Inc. (NASDAQ:IMMX) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 150,082 shares of the company’s stock after purchasing an additional 7,954 shares during the quarter. Geode Capital Management LLC owned approximately 0.55% of Immix Biopharma worth $224,000 as of its most recent filing with the SEC. 11.26% of the stock is owned by institutional investors.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.